Optimata Granted Patent for Granulopoiesis-Modelling System
News Sep 13, 2007
Optimata Ltd. announced that it has been granted U.S. Patent 7,266,483 for a system and method that models granulopoiesis and that can optimize drug therapies in order to reduce or prevent neutropenia. Neutropenia is a shortage of neutrophils in the blood and a toxic condition that often occurs during chemotherapy.
Optimata’s technology comprises a computerized biosimulation system and a computer-implemented method for optimizing drug therapies that affect neutropenia. The patent covers optimization methods and systems applied to both individual and patient populations.
The technology can predict the impact of drug regimens on neutrophil levels in the blood and can be applied to optimize the development of new drug therapies (both monotherapy and combination therapy) so as to alleviate their myelotoxicity; to optimize the development of supportive drug treatments; and to repurpose existing drugs whose use or development has been limited or discontinued because of toxic side effects.
“This patent joins our previously-granted patent for optimizing the development of thrombocytopenia-affecting drugs and reinforces Optimata's leadership position in the field of predictive toxicity,” said Guy Malchi, CEO of Optimata.
“By using the integrated predictive powers of Optimata's Virtual Patient Engine, Optimata and its drug development partners have the benefit of an 'early warning system' for two of the leading toxic consequences of oncological drug failure – neutropenia and thrombocytopenia.”
'Body-on-a-Chip' Could Advance Drug EvaluationNews
MIT engineers have developed new technology that could be used to evaluate new drugs and detect possible side effects before the drugs are tested in humans. Using a microfluidic platform that connects engineered tissues from up to 10 organs, the researchers can accurately replicate human organ interactions for weeks at a time.READ MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.
Study Debunks Fears of Increased Teen Suicide Risk From TamifluNews
Researchers from the University of Illinois at Chicago suggests that the drug oseltamivir - commonly known as Tamiflu - does not cause an increased risk of suicide in pediatric patients.READ MORE